RMD
Status-Quo-PlayerResMed
$230.26
+0.62%
as of 13 Apr
Power Core
ResMed's moat is the integration of a dominant installed device base with a proprietary cloud data ecosystem that creates compounding switching costs across patients, clinicians, and payers simultaneously.
Direction of Movement
Lateral With Upward Bias as Fundamentals Diverge From Narrative
ROC 200
-11.0%
Direction Signals
- Signal 1: Accelerating mask and device revenue growth despite the GLP-1 narrative. ResMed has reported consistent revenue growth in its Sleep and Breathing Health segment through fiscal year 2025 and into fiscal 2026, driven by both new patient starts and the resupply consumables flywheel. Gross margins have expanded, reflecting favorable product mix (more masks, higher-margin AirSense 11 devices) and manufacturing efficiency. The disconnect between improving fundamentals and declining stock price is a hallmark of narrative-driven repricing rather than fundamental deterioration. Device sell-through data from major HME providers has not shown the demand destruction that a genuine GLP-1 substitution effect would produce.
- Signal 2: The Philips competitive void persists. Philips Respironics has made progress in returning devices to market, but its re-entry has been slow and constrained by ongoing litigation, regulatory scrutiny, and damaged physician and patient trust. As of early 2026, Philips has not meaningfully recaptured the market share lost during the recall period. ResMed's installed base advantage, built during the 2021 to 2024 window, continues to compound through mask resupply and data platform stickiness. Every quarter that passes without a full Philips recovery entrenches ResMed's position further.
- Signal 3: GLP-1 clinical data increasingly supports coexistence, not substitution. Longitudinal data from GLP-1 trials, including real-world evidence emerging from large patient populations, suggests that while GLP-1 drugs reduce AHI in obese OSA patients, a significant percentage of treated patients retain clinically meaningful sleep apnea requiring PAP therapy. Furthermore, GLP-1 discontinuation rates (estimated at 30 to 50% within the first year in some real-world datasets) raise questions about the durability of weight loss and associated AHI improvements. ResMed management has publicly cited the potential for GLP-1 drugs to expand the diagnosed population by driving clinical encounters in which sleep screening occurs. Early indications from sleep lab referral patterns in GLP-1 prescriber networks appear consistent with this thesis, though definitive evidence remains forthcoming.
- Signal 4: Software segment growth and margin accretion. ResMed's Residential Care Software segment has shown steady organic growth, and the company's SaaS revenue provides a higher-margin, more predictable revenue stream that diversifies the business mix away from pure device economics. While this segment remains smaller than Sleep and Breathing Health, its growth trajectory and strategic integration into ResMed's broader out-of-hospital care vision provide a secondary growth vector that the market has largely undervalued during the GLP-1 focused sell-off.
For more than three decades, ResMed has occupied a peculiar and powerful position in global healthcare: the company that turns a disorder most people ignore into a recurring revenue machine. Sleep apnea affects an estimated one billion people worldwide, yet the vast majority remain undiagnosed. ResMed does not merely sell devices to treat this condition. It has built an integrated ecosystem of hardware, masks, cloud software, and remote monitoring that captures patients at diagnosis and retains them through a lifecycle of consumable replacements and data-driven care management. This is not a medical device company in the traditional sense. It is a chronic disease management platform disguised as a CPAP manufacturer.
The central analytical question facing ResMed in spring 2026 is whether its structural dominance in sleep-disordered breathing can withstand the simultaneous pressure of GLP-1 receptor agonist drugs (like Ozempic and Mounjaro), which have demonstrated weight loss effects that may reduce sleep apnea severity, and the emergence of alternative treatment modalities. Since mid-2023, the "GLP-1 narrative" has weighed on ResMed's valuation, at times severely, despite the company's continued revenue growth and margin expansion. The stock sits approximately 24% below its 52-week high, with negative 200-day price momentum of minus 11%, reflecting persistent market skepticism about the durability of the addressable market itself.
The L17X insight here is structural: GLP-1 drugs do not eliminate sleep apnea, they may expand the pool of diagnosed patients by driving millions of people into clinical settings where screening occurs. The real threat to ResMed is not a competing therapy. It is the possibility that the market narrative permanently reprices the company's terminal growth rate before the data proves the narrative wrong. ResMed's moat is clinical, not commercial. The question is whether Wall Street can distinguish between the two.
This analysis continues with 6 more sections.
Continue reading: Role Assignment · Strategic Environment · Dependency Matrix · Self-Image & Mission · Direction of Movement · Portfolio Lens
Read full analysis — freeCreate a free account. No credit card. No trial period.